Circulating microRNAs have a sex-specific association with metabolic syndrome by unknown
Wang et al. Journal of Biomedical Science 2013, 20:72
http://www.jbiomedsci.com/content/20/1/72RESEARCH Open AccessCirculating microRNAs have a sex-specific
association with metabolic syndrome
Yu-Ting Wang1,3, Pei-Chien Tsai2, Yi-Chu Liao4,5, Chung-Y Hsu7,8 and Suh-Hang Hank Juo1,2,6*Abstract
Background: The microRNAs let-7 g and miR-221 have been demonstrated to be related to the glucose
metabolism. This study assessed the serum levels of these two microRNAs in subjects with and without metabolic
syndrome (MetS).
Results: The serum microRNA levels were detected in 102 subjects aged 40 to 80 years who were recruited from
the general population. The status of MetS was defined by the Adult Treatment Panel III (ATP III) criteria modified
for Asians. Subjects with histories of cardiovascular diseases or who were receiving treatment with hypoglycemic or
lipid-lowering agents were excluded. The levels of both circulating microRNAs (let-7 g and miR-221) were higher in
subjects with MetS (p = 0.004 and p = 0.01, respectively). The sex-specific analysis showed that the difference was
more prominent in women (for both miRNAs, p < 0.05 in women and p > 0.1 in men). In the female subjects,
increased expression of both microRNAs was associated with an increased number of MetS risk components
(p = 0.002 for let-7 g and p = 0.022 for miR-221). Moreover, the elevation of serum let-7 g was significantly
associated with a low level of high-density lipoprotein cholesterol (p = 0.022) and high blood pressure (p = 0.023).
In contrast, the miR-221 level was not associated with any individual MetS risk component.
Conclusions: The circulating levels of let-7 g and miR-221 displayed a female-specific elevation in individuals with
metabolic syndrome.
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Metabolic syndrome (MetS) has become a global health
issue due to its contribution to an increased risk of type 2
diabetes, cardiovascular (CV) complications, and mor-
tality. MetS features a clinical phenotype of abdominal
adiposity, insulin resistance, hypertension, dyslipidemia,
inflammation, and a prothrombotic state. The associations
between MetS and chronic inflammation [1], insulin
resistance [2], or incident CV events [3] have been presen-
ted differently between men and women. Furthermore, a
recent study demonstrated that gender is a significant
effect modifier for MetS-related CV deaths, non-CV
deaths, and total mortality [4].* Correspondence: hjuo@kmu.edu.tw
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reproduction in any medium, provided the orMicroRNAs (miRNAs), which are endogenous non-
coding small RNAs, are involved in the post-
transcriptional regulation of gene expression through
the suppression of mRNA translation or the degradation
of mRNA. More than 60% of the human protein-coding
genes are expected to have miRNA target sites in their
3’-untranslated region (3’-UTR); therefore, miRNAs are
considered to likely be involved in the pathogenesis of
diseases [5-8]. An ample of evidence indicates that
miRNAs can be detected in the circulation [9,10]. After
being released into the extracellular fluids, miRNAs play
roles in cell-to-cell communication within the same
tissue or between the same and different cell types in re-
mote tissues by the methods of endocytosis-like interna-
lization or receptor-ligand interactions [11].
One recent study compared subjects with MetS to
individuals manifesting only one of metabolic disorders
[type 2 diabetes, hypercholesterolemia, or hypertension]
showed that blood miR-197, miR-23, and miR-509-5p
positively correlated with body mass index, and elevatedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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high blood pressure [12]. Using in silico analysis, the au-
thors predicted that the target genes of these 5 miRNAs
may involve in the pathways related to shingolipid and
fatty acid metabolisms and the vascular signaling. Meta-
bolic syndrome is a diseased condition which affects
both adipose tissue and vascular walls. Extracellular
miRNAs may mediate the intercellular communication.
The adipocyte-derived microvesicles contained not only
bioactive proteins but also miRNAs, including let-7b and
miR-103, 143, 146b, 148, 155, and 221 [13]. Of these,
let-7b, miR-143, and 221 have been demonstrated to
regulate both atherogenic and adipogenic processes [13].
Heneghan et al. compared the expression profiles of cir-
culating miRNAs between morbidly obese patients and
non-obese individuals and found miR-132 and miR-17-
5p were significantly decreased in obese subjects [14].
The level of miR-17-5p inversely correlated with body
mass index and it may regulate adipocyte differentiation
by targeting Rb2/p130. In the same article, the data did
not confirm differences in the levels of circulating miR-
34a, 99a, 122, 143, 145, and 195 between subjects in the
two groups. However, the authors did not make a men-
tion of let-7 or miR-221.
Previous publications have indicated that the let-7
family plays an important role in glucose metabolism.
Using Cre-inducible let-7-transgenic mice, Frost and
Olson [15] reported that the global overexpression of
let-7 resulted in glucose intolerance and decreased insu-
lin secretion from the pancreas. The knockdown of let-7
can prevent and treat obesity-induced glucose intoler-
ance by restoring the expression of the insulin receptor
and insulin receptor substrate 2 in the muscle and liver
of mice fed a high-fat diet [15]. Zhu et al. also found that
Lin28a/b and let-7 can coordinately regulate the glucose
metabolism through the activation and suppression of
the insulin-PI3K-mTOR signaling pathway, respectively
[16]. In vitro studies have shown that high glucose (HG)
upregulates miR-221 expression in human umbilical vein
endothelial cells and results in impaired endothelial
cell migration through the suppression of the c-kit
gene [17]. A reduction of the miR-221 levels through
its anti-sense oligonucleotide could restore the pro-
duction of the c-kit protein and weaken the HG-
induced inhibition of cell migration. The levels of
miR-221 are increased in adipocytes derived both
from mice under a high-fat diet [18] and obese human
subjects [19]. In addition, miR-221 can be upregulated in
3 T3-L1 adipocytes treated with tumor necrosis factor-
alpha [20].
In the present study, we have found the association of
two circulating microRNAs (let-7 g and miR-221) with
metabolic syndrome in human subjects, more prominent
in women. The over-expression of the two microRNAsin the circulation may have implications for MetS related
CV complications.
Methods
Study population and definition of metabolic syndrome
The subjects in this study (aged between 40 and 80 years)
were enrolled from the general population who had
volunteered to participate in ongoing genetic studies re-
lated to cardiovascular diseases and metabolic syndrome
at the Kaohsiung Medical University Hospital between
Jan 2010 and Sep 2011. All of the participants provided
written informed consent. To reduce the effect from
existing major cardiovascular diseases, subjects who self-
reported coronary artery disease, myocardial infarction,
stroke, or peripheral arterial occlusive disease were ex-
cluded from the study. In addition, subjects who were
taking medication for hyperglycemia or hyperlipidemia
were also excluded. At the study entry, 122 subjects
were enrolled but 20 were excluded due to the presence
of hemolysis. Metabolic syndrome was diagnosed in
patients who exhibited three or more of the following
symptoms, which are defined by the Adult Treatment
Panel (ATP) III criteria modified for Asians: 1) waist
circumstance greater than 90 cm in men and greater
than 80 cm in women, 2) systolic blood pressure greater
than 130 mmHg, diastolic blood pressure greater than
85 mmHg, or previously diagnosed hypertension with
treatment, 3) fasting glucose level greater than 100 mg/dl
or previously diagnosed diabetes mellitus with treatment,
4) fasting triglycerides greater than 150 mg/dl, and 5)
high-density lipoprotein (HDL) cholesterol less than
40 mg/dl in men and less than 50 mg/dl in women. The
classification of metabolic syndrome from 0–5 was based
on the number of abnormal metabolic components de-
fined by the above criteria. A subject who reported never
having smoked was defined as a never smoker. A subject
who had previously smoked in his/her lifetime was de-
fined as a smoker. Because the median age of natural
menopause in Chinese women is 50 years [21,22], we
further separated the women by this age cutoff for an
exploratory analysis.
Serum preparation and hemoglobin measurement for
hemolysis
Within 1 h after sample collection, the fasting venous
blood was centrifuged at 3,000 g and 4°C for 10 min.
The serum was stored immediately at −80°C until fur-
ther use. To determine the degree of hemolysis in the
samples, 200 μl of sodium carbonate solution (0.01%
Na2CO3) was added to 20 μl of each serum sample (10:1
dilution). After vortex mixing and incubating at room
temperature for 1 h, the free oxy-hemoglobin in the
serum was measured using a spectrophotometer at an
absorbance wavelength of 415 nm (A415) [23]. Higher
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of hemolysis in the serum. The cutoff A415 value of 0.2
was used to distinguish the hemolyzed from the non-
hemolyzed samples [24].
Isolation of total RNA and miRNA from serum
The serum total RNA, including miRNAs, was extracted
using the MasterPure™ Complete DNA and RNA Purifi-
cation Kit (Epicentre, an Illumina company, USA) accor-
ding to the manufacturer’s instructions. After effective
denaturation of the proteins in serum during RNA isola-
tion, we added 1 μl of 5 nM synthetic, non-human
miRNA (syn-cel-lin-4) into 50 μl of each serum sample
as an internal control for the normalization of the real-
time PCR results. The final RNA products were quanti-
fied by absorbance measurements at 260 nm (A260) and
280 nm (A280). The A260/A280 values were higher than
1.6 for all of the samples.
Quantification of miRNAs: real-time quantitative PCR
The mature miRNAs were measured using TaqMan-
based qRT-PCR methods according to the manufac-
turer’s instructions (Applied Biosystems, Foster City,
CA, USA). The reverse transcription reactions were
performed in scaled-down reaction volumes (8 μl) under
the following conditions: 16°C for 30 min, 42°C for
30 min, and 85°C for 5 min. The real-time PCR reac-
tions were performed in duplicate in scaled-down reac-
tion volumes (10 μl) on an ABI Prism 7900 Sequence
Detection System under the following conditions: 95°C
for 10 min, followed by 40 cycles at 95°C for 15 sec and
60°C for 1 min. The data were analyzed using the SDS
Software version 2.4 (Applied Biosystems, Inc.), and a
miRNA with a Ct value greater than 36 was considered
undetectable. The analysis across the samples was
conducted using a median normalization method with a
spiked-in synthetic C. elegans miRNA (syn-cel-lin-4) as
the control [10]. The normalization factors were obtained
after subtracting the measured Ct of syn-cel-lin-4 for each
sample of interest from the median value of all of the
samples. Then, the normalization factor was added to the
raw Ct of every candidate miRNA in the same sample.
Finally, the adjusted data (Ct’) was treated as the
median-normalized Ct value. The expression level of
a circulating miRNA was calculated as 2-Ct’ with a loga-
rithmic transformation.
Statistical analysis
JMP (version 8.0) and PASW Statistics (version 18) were
used for all statistical analyses. To evaluate the baseline
characteristics and the risk components of MetS, Chi-
square analyses and t-test were applied for the categor-
ical and continuous variables, respectively. Comparisons
of the levels of circulating miRNAs between the twogroups were conducted by the non-parametric Mann–
Whitney U tests because the data were not normally
distributed. The relationship between the number of
MetS components and the expression of both miRNAs
was tested through the Jonckheere-Terpstra test. Corre-
lation coefficients were used to examine the relation-
ships between the value of each MetS risk component
and the expression level of a miRNA. A difference with
p < 0.05 was considered statistically significant.
Results
Clinical characteristics of the study population
Because hemolysis can increase the serum microRNA
levels due to red blood cells (RBC)-derived microRNAs
[24], we excluded 20 serum samples that exceeded the
hemolysis cutoff value (see Method section for details).
Therefore, 102 samples were subjected to further ana-
lysis. The demographic characteristics and the status of
MetS in these 102 subjects are shown in Table 1. There
were 31 MetS subjects and 71 non-MetS. In general, the
distributions of sex, age, prevalence of diabetes, and
smoking status were similar between the groups with or
without MetS. The characteristics between men and
women in respect of their MetS status are also shown in
Table 1. The prevalence of each risk component between
genders according to the sum of abnormal components
of the MetS is shown in Table 2. Of the five components
of MetS, large waist circumstance was the most com-
mon risk factor in both genders, followed by high blood
pressure. However, a higher prevalence of decreased
HDL cholesterol was noted in women (28%) than in
men (13.5%), whereas fasting hyperglycemia was more
common among men (36.5%) than women (24%).
Differential expression of circulating miRNAs between
MetS and non-MetS subjects
The comparisons between the MetS (n = 31) and the
non-MetS subjects (n = 71) showed that the levels of
both let-7 g and miR-221 were significantly elevated in
the circulation of the MetS subjects (p = 0.004 for let-7 g
and p = 0.01 for miR-221, Figure 1A and 1B). We further
analyzed the relationship between the miRNAs levels
and the number of MetS risk components. The levels of
the two miRNAs were elevated with increasing numbers
of MetS risk components: 0–2 components (n = 71),
3 components (n = 22), and 4–5 components (n = 9;
p = 0.004 for let-7 g and p = 0.007 for miR-221, Figure 1C
and 1D).
Relationship between miRNAs and the MetS components
We further tested the relationship between each miRNA
and each individual MetS component (Figure 2). Of the
five components of MetS and the two obesity parame-
ters (body mass index and waist-hip ratio), the HDL
Table 1 Characteristics of the subjects with and without metabolic syndrome
All (n = 102) Men (n = 52) Women (n = 50)
without MS with MS p value without MS with MS p value without MS with MS p value
Total number 71 31 36 (69.2%) 16 (30.8%) 35 (70.0%) 15 (30.0%)
Age (yr) 55.5 ± 7.8 56.5 ± 8.5 > 0.1 56 ± 9 55 ± 8 > 0.1 55 ± 6 58 ± 9 > 0.1
Smoker, n (%) 10 (14.1%) 4 (12.9%) > 0.1 10 (27.8%) 4 (25.0%) > 0.1 0 (0.0%) 0 (0.0%) 1.000
Hypertension, n (%) 14 (19.7%) 19 (61.3%) < 0.0001 8 (22.2%) 11 (68.8%) 0.001 6 (17.1%) 10 (53.3%) 0.009
Anti-HTN drugs, n (%) 5 (7.0%) 6 (19.4%) 0.07 2 (5.6%) 4 (25%) 0.06 3 (8.6%) 2 (13.3%) > 0.1
Systolic BP (mmHg) 114 ± 13 129 ± 13 < 0.0001 116 ± 12 128 ± 14 0.004 111 ± 13 131 ± 13 < 0.0001
Diastolic BP (mmHg) 71 ± 10 79 ± 9 0.0003 72 ± 10 79 ± 9 0.020 70 ± 10 79 ± 9 0.007
Diabetes, n (%) 2 (2.8%) 2 (6.5%) > 0.1 1 (2.8%) 1 (6.3%) > 0.1 1 (2.9%) 1 (6.7%) > 0.1
Fasting sugar (mg/dl) 94 ± 18 107 ± 19 0.0013 93 ± 9 107 ± 15 0.001 91 ± 7 107 ± 23 0.0006
Body weight (kg) 63.0 ± 11.2 70.5 ± 12.6 0.0033 69.0 ± 10.7 77.6 ± 8.8 0.008 56.7 ± 7.8 63.0 ± 12.0 0.031
Body mass index (kg/m2) 24.1 ± 3.3 26.6 ± 3.6 0.0008 24.3 ± 3.4 26.9 ± 2.4 0.007 23.8 ± 3.2 26.2 ± 4.5 0.042
Waist circumference (cm) 82.7 ± 9.2 90.7 ± 7.5 < 0.0001 84.9 ± 8.6 92.3 ± 6.1 0.001 80.5 ± 9.5 89.0 ± 8.7 0.005
Waist-hip ratio 0.87 ± 0.07 0.92 ± 0.06 0.0019 0.89 ± 0.05 0.93 ± 0.04 0.006 0.85 ± 0.08 0.90 ± 0.07 0.046
Triglyceride (mg/dl) 95 ± 39 164 ± 93 0.0003 98 ± 45 166 ± 95 0.013 92 ± 32 163 ± 95 0.013
HDL cholesterol (mg/dl) 60 ± 14 50 ± 14 0.0008 55 ± 11 45 ± 10 0.003 66 ± 14 56 ± 15 0.022
Total cholesterol (mg/dl) 209 ± 39 216 ± 35 > 0.1 202 ± 38 209 ± 37 > 0.1 217 ± 38 224 ± 33 > 0.1
The data are expressed as a number (percentage) or mean ± SD. MS, metabolic syndrome; HTN, hypertension, BP, blood pressure, HDL, high density lipoprotein.
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nificant correlation with the level of circulating let-7 g
(r = −0.212, p = 0.033 and ρ = −0.218, p = 0.028 by
Pearson’s and Spearman’s correlation, respectively). The
finding suggests that plasma HDL cholesterol has an
inverse relationship with the level of let-7 g in the circu-
lation. The similar result was obtained after adjusting for
age and smoking status (β = −0.017, 95% confidence
interval = −0.031 ~ −0.004, p = 0.014 by multiple linear
regression).
Differential expression of circulating miRNAs between
men and women
The sex-specific analysis showed that the miRNA ex-
pression levels were distinct between men and womenTable 2 Prevalence of individual metabolic syndrome compon
abnormal components
Men
Number of abnormal metabolic comp
0-5 0-2 3
(All) (without MS) (with MS)
(n = 52) (n = 36) (n = 12)
Increased waist circumstance 25 (48.1%) 12 (33.3%) 9 (75.0%)
Decreased HDL 7 (13.5%) 0 (0.0%) 4 (33.3%)
Hypertriglycerides 10 (19.2%) 2 (5.6%) 6 (50.0%)
Hyperglycemia 19 (36.5%) 8 (22.2%) 7 (58.3%)
High blood pressure 24 (46.2%) 10 (27.8%) 10 (83.3%)
The data are expressed as a number (percentage). MS, metabolic syndrome, HDL, h(Figure 3). Among the males (n = 52), the serum miRNA
levels were not significantly different between the MetS
(n = 16) and the non-MetS (n = 36) individuals (p > 0.1
for both miRNAs). In contrast, the two miRNAs were
significantly overexpressed in the female subjects with
MetS (n = 15) compared with those without MetS (n = 35;
p = 0.002 for let-7 g; p = 0.032 for miR-221). Remarkably,
the increased level of either miRNAs was paralleled with
an increased number of MetS risk components. However,
the statistical significance was only observed in the
women subjects (p = 0.002 for let-7 g; p = 0.022 for miR-
221). Among the females, each MetS component was
defined as high or low using the abovementioned ATPIII
definition. A higher level of circulating let-7 g was signifi-
cantly associated with a higher blood pressure (p = 0.023)ent in men and women according to the number of
Women
onents Number of abnormal metabolic components
4-5 0-5 0-2 3 4-5
(with MS) (All) (without MS) (with MS) (with MS)
(n = 4) (n = 50) (n = 35) (n = 10) (n = 5)
4 (100.0%) 31 (62.0%) 18 (51.4%) 8 (80.0%) 5 (100.0%)
3 (75.0%) 14 (28.0%) 5 (14.3%) 4 (40.0%) 5 (100.0%)
2 (50.0%) 9 (18.0%) 2 (5.7%) 2 (20.0%) 5 (100.0%)
4 (100.0%) 12 (24.0%) 3 (8.6%) 6 (60.0%) 3 (60.0%)




p = 0.004 p = 0.004
p = 0.01 p = 0.007
(B)
(A)
Figure 1 Differential expression of serum miRNAs in individuals with or without MetS. (Left: A and B) Comparisons were made between
subjects without MetS (n = 71) and with MetS (n = 31) through non-parametric Mann–Whitney U tests. The box plots depict the 25th-75th
percentile, and the white line represents the median of each contribution. (Right: C and D) The relationships between the number of MetS risk
components and the levels of miRNA was analyzed through Jonckheere-Terpstra tests. The status of MetS was converted into an ordinal variable:
MetS 0–2 (n = 71), MetS 3 (n = 22), and MS 4–5 (n = 9). Differences with p < 0.05 were statistically significant.
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The serum miR-221 level did not exhibit any correlation
with any of the MetS risk components.
Discussion
The present study revealed that two miRNAs (let-7 g
and miR-221) are notably overexpressed in the serum of
individuals with MetS. The sex-specific analysis implied
that the two miRNAs are more significantly associated
with MetS in women. The level of either miRNAs in-
creased when the number of MetS risk components in-
creased. Furthermore, let-7 g may also affect individual
MetS risk components: an increase in the let-7 g level
was correlated with a high blood pressure and a low
HDL cholesterol level. However, miR-221 may have a
less distinguishable effect on the individual risk compo-
nents. Our data suggest that circulating let-7 g and miR-
221 may be associated with the development of MetS.
Intracellular miRNAs can be secreted into an extracel-
lular environment through two distinct mechanisms:
intra-vesicular transport (exosomes, microparticles, and
apoptotic bodies) and extra-vesicular transport (protein
and lipoprotein complexes) [11]. Secreted extracellular
miRNAs serve as signaling molecules and mediate inter-
cellular crosstalk. The present available data have been
demonstrated that microvesicle-enclosed and lipoprotein-
delivered miRNAs can be transferred into recipient cellsand further influence cell phenotypes and functions
[25,26]. However, the exact mechanism of the release for
an individual miRNA from different cell types is largely
unknown.
Another implication of our data is that the elevated
levels of circulating let-7 g and miR-221 in the MetS
subjects may affect CV complications. Vascular endo-
thelial cells (ECs), circulating endothelial progenitor cells
(EPCs), and peripheral blood components can be in
direct contact, and ECs and EPCs are exposed to circu-
lating exosomes containing miRNAs that may influence
the function of these cells and eventually contribute to
cardiovascular diseases. The biological functions of
miRNAs in vascular walls are cell-specific. Our recent
publication demonstrated that let-7 g is involved in
lipid-mediated atherosclerosis by negatively regulating
an oxidized low-density lipoprotein receptor, LOX-1
[27]. Transfection of let-7 g into human aortic smooth
muscle cell inhibited LOX-1 and the transcriptional fac-
tor OCT-1 expression, cell proliferation and migration.
In addition, we also demonstrated that let-7 g could be
downregulated in the aorta of mice fed a high-fat diet
and that this result was accompanied by an increase in
the expression of LOX-1. The present study demon-
strated that an increase in the serum let-7 g level is
associated with high blood pressure and low HDL
cholesterol levels in women. Both high blood pressure
Figure 2 The associations between the individual miRNAs and the MetS risk components. Correlations between the expression level of the
circulating miRNAs and the individual component of metabolic syndrome. The relationships were assessed by Pearson’s and Spearman’s
correlation (r, Pearson’s correlation coefficient; ρ,Spearman’s coefficient). HDL, high-density lipoprotein cholesterol; BP, blood pressure.
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p > 0.1 p > 0.1 p = 0.032 p = 0.022
p > 0.1 p > 0.1 p = 0.002 p = 0.002
Figure 3 Differential expression of serum miRNAs in male and female subjects with and without MetS. The sample sizes of the male and
female subjects were the following: MS(−) n = 36, MS(+) n = 16 in men and MS(−) n = 35, MS(+) n = 15 in women. (Left section) The comparisons
between the individuals without or with MetS were conducted through non-parametric Mann–Whitney U tests. The box plots depict the 25th-
75th percentile, and the white line represents the median of each contribution. (Right section) The relationships between the number of MetS
risk components and the miRNA levels were analyzed by Jonckheere-Terpstra tests. The status of MetS was converted into an ordinal variable: MS
score 0–2 (n = 36 in men and n = 35 in women), MS score 3 (n = 12 in men and n = 10 in women), and MS score 4–5 (n = 4 in men and n = 5 in
women). Differences with p < 0.05 were statistically significant.
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nection with LOX-1 overexpression in atherosclerotic
lesions [28,29]. It is possible that circulating let-7 g can
be taken up by vascular smooth muscle cells (VSMC) to
inhibit LOX-1 expression. Therefore, we hypothesize
that the elevated circulating let-7 g levels in MetS sub-
jects can be a defense mechanism through which the
body fights an unfavorable lipid profile. Conversely, the
elevation of the circulating miR-221 levels may aggravate
the process of atherosclerosis. A previous investigation
showed that the level of miR-221 in EPCs was higher in
patients with coronary artery disease and the miR-221
expression inversely correlated with the number of EPCs
[30]. Zhang X et al. further demonstrated that miR-221
overexpression inhibited the proliferation of endothelial
progenitor cells by directly targeting PAK1 and affecting
the c-Raf/MEK/ERK pathway [31]. An in vivo study in
rats also indicated that the downregulation of miR-221
and miR-222 can reduce the proliferation of VSMCs and
neointimal hyperplasia, both of which play important
roles in arterial restenosis after intima injury [32]. It ispossible that the circulating miR-221 can be taken up by
these cells and that this action might interfere with cell
growth. However, further studies are necessary to confirm
these findings.
Recent studies suggest that the contribution of individ-
ual metabolic syndrome component to relative risks of
cardiovascular diseases and heart failure differs between
genders [2,3,33]. A number of mechanisms have been
considered for the gender disparity in MetS-associated
cardiovascular sequelae, including sex hormones, neuro-
vascular regulation, and intrinsic myocardial geometry
and function [3]. One 12-year observational study demon-
strated that the association between MetS and all-cause,
cardiovascular, and cardiac mortality was only seen in
postmenopausal women [4]. However, the reasons for the
lack of significant relationship in men and premenopausal
women were unclear. The current study indicated that the
elevation of the circulating let-7 g and miR-221 levels was
predominant in MetS women. Of interest, 80% of the
female subjects with MetS were above the median age
(50 years) of natural menopause in Chinese women.
Figure 4 Comparisons of the expression profiles of circulating miRNAs in women according to each abnormal components of MetS.
Female subjects were separated to two groups using the criteria of individual MetS components. * Significant difference (p < 0.05) between the
groups adjusted by age. All of the data were analyzed through non-parametric Mann–Whitney U tests. WC, waist circumstance; HDL, high-density
lipoprotein cholesterol; TG, triglycerides; AC, fasting blood sugar; BP, blood pressure; TCHO, total cholesterol.
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tors to cardiovascular risks, in our study the expression of
circulating let-7 g and miR-221 were not correlated with
age, and none of women had the smoking habit. Beyond
their roles in glucose metabolism, let-7 g and miR-221
play a prominent role in vascular smooth muscle cells and
endothelial cells [34]. Our data provide a potential clue to
explore the changes of vascular pathology in individuals
with MetS, especially in women. Further investigations are
required to understand how let-7 g and miR-221 affect
MetS-related cardiovascular complications.
It is not uncommon to find sex-specific risk factors for
common diseases. Similarly, miRNA studies have also
reported a sex-specific pattern. A previous investigation
demonstrated that the expression of miR-30b in the
brain cortex of schizophrenic patients was only reduced
in female subjects [35]. The study further showed that
miR-30b can be regulated by estrogen signaling in neur-
onal tissues. In our study, there was no difference in the
expression levels of let-7 g and miR-221 between women
younger (n = 11) and older (n = 39) than the age of
50 years (−9.16 vs. -9.08 for let-7 g and −9.07 vs. -9.08
for miR-221; p > 0.1 for both miRNAs). Although the
absence of evidence that supports a difference in the
miRNA levels between the women in these two agegroups, our current data implies that the menopausal
status might not be a major confounder in the relation-
ship between the two miRNAs and MetS. In addition,
we observed a similar increased pattern of circulating
miRNAs in the male subjects with MetS. However, the
lack of statistical significance could be due to the small
sample size and the larger subsample variation in the
serum miRNA levels among men without MetS. In our
study, the higher prevalences of hypertension (22.2%)
and smoking status (27.8%) in the non-MetS men may
be a confounder to the variances.
Another important finding in this study was that the
percentage of hemolyzed samples was much higher in
the subjects with MetS compared with those without
MetS (35.4% vs. 4.1%, p < 0.0001). Hemolysis is a major
factor for the false results that are obtained in routine
blood biochemistry examinations. It is also known that
hemolysis will cause a release of RBC-derived miRNAs
into the serum [24]. Thus, even if the degree of
hemolysis is low, the interference may be substantial if
there is a low abundance of miRNAs in the serum.
Hemolysis can take place in vivo, in vitro, or both. In the
present study, the procedures used for sample collection,
handling, and centrifugation were performed under the
same protocols. Of the 20 samples that were discarded
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17 were collected from MetS subjects. Further analysis
showed that the 20 discarded samples exhibited signifi-
cantly lower (p = 0.0012) HDL cholesterol (46 mg/dl)
compared with the analyzed samples (57 mg/dl). Simi-
larly, the 20 samples also had a higher level of trigly-
cerides (264 mg/dl vs. 116 mg/dl, p < 0.0001). Therefore,
the possible reasons for the disproportionate amount of
hemolysis in MetS subjects include difficult vascular
access due to potential atherosclerosis or changes in the
RBC membrane properties [36]. The change in the
circulating levels of let-7 g and miR-221 might be the
net result of many microvesicles secreted from distinct
tissue cells. However, let-7 g is enriched in both reticulo-
cytes and erythrocytes, whereas miR-221 is a reticulo-
cyte-specific miRNA [37]. If hemolysis had not been
excluded, we would have overestimated the strength of
the association between these two miRNAs and the
occurrence of MetS.
Conclusions
Overall, we observed higher circulating levels of let-7 g
and miR-221 in female subjects with MetS. However,
this pattern was not detected in the male subjects.
Further large-scale studies are needed to validate our
findings.
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